1. Home /
  2. Pharmaceuticals

Pharmaceuticals

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land

These two firms have successful drugs and could make nice additions for larger companies.

Novocure Could Climb Even Further; Here's Where to Buy

Novocure Could Climb Even Further; Here's Where to Buy

The oncology company already has risen significantly this year, but its charts indicate the rally could continue.

Pacific Bio Shares Fall on U.K. Antitrust Concern About Illumina Deal

Pacific Bio Shares Fall on U.K. Antitrust Concern About Illumina Deal

Initial inquiry into deal showed it could remove what might be most significant competitive threat to Illumina.

New Targets for Merck Stock as Charts Point Higher

New Targets for Merck Stock as Charts Point Higher

Investors and traders should approach MRK from the long side.

Bulls Walk the Market Up Slowly, but Keep One Eye on Fed

Bulls Walk the Market Up Slowly, but Keep One Eye on Fed

I'm inclined to add to Disney on today's weakness.

Don't Jump Into Charles River Labs Just Yet

Don't Jump Into Charles River Labs Just Yet

CRL could weaken further in upcoming weeks for a better buying opportunity.

IPO Gives Chinese Couple a 'Hansoh' Sum

IPO Gives Chinese Couple a 'Hansoh' Sum

The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.

ArQule Jumps on Positive Phase 1 Blood Cancer Trial Results

ArQule Jumps on Positive Phase 1 Blood Cancer Trial Results

The company is testing its hematologic malignancies treatment.

Kura Oncology Soars After Lymphoma Treatment Test Results

Kura Oncology Soars After Lymphoma Treatment Test Results

Kura Oncology climbs after the clinical-stage biopharmaceutical company says a phase 2 trial of its lymphoma treatment tipifarnib showed encouraging results.

Savara Plunges After Lung Disease Drug Fails Phase 3 Trial

Savara Plunges After Lung Disease Drug Fails Phase 3 Trial

The stock falls below $3 after closing Wednesday's session at $10.57.